HK1068136A1 - Muscarinic antagonists - Google Patents

Muscarinic antagonists

Info

Publication number
HK1068136A1
HK1068136A1 HK05100696.2A HK05100696A HK1068136A1 HK 1068136 A1 HK1068136 A1 HK 1068136A1 HK 05100696 A HK05100696 A HK 05100696A HK 1068136 A1 HK1068136 A1 HK 1068136A1
Authority
HK
Hong Kong
Prior art keywords
sup
formula
compound
muscarinic antagonists
methods
Prior art date
Application number
HK05100696.2A
Other languages
English (en)
Inventor
Craig D Boyle
William J Greenlee
Samuel Chackalamannil
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HK1068136A1 publication Critical patent/HK1068136A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
HK05100696.2A 2002-04-26 2005-01-26 Muscarinic antagonists HK1068136A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37609302P 2002-04-26 2002-04-26
PCT/US2003/012694 WO2003091220A1 (en) 2002-04-26 2003-04-24 Muscarinic antagonists

Publications (1)

Publication Number Publication Date
HK1068136A1 true HK1068136A1 (en) 2005-04-22

Family

ID=29270760

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05100696.2A HK1068136A1 (en) 2002-04-26 2005-01-26 Muscarinic antagonists

Country Status (12)

Country Link
US (1) US6890936B2 (de)
EP (1) EP1499596B1 (de)
JP (2) JP4527408B2 (de)
CN (1) CN1649845A (de)
AT (1) ATE413388T1 (de)
AU (1) AU2003228674A1 (de)
CA (1) CA2484217A1 (de)
DE (1) DE60324544D1 (de)
ES (1) ES2315494T3 (de)
HK (1) HK1068136A1 (de)
MX (1) MXPA04010552A (de)
WO (1) WO2003091220A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004233863B2 (en) 2003-04-24 2010-06-17 Incyte Holdings Corporation Aza spiro alkane derivatives as inhibitors of metalloproteases
CN101948462A (zh) * 2004-09-20 2011-01-19 塔加西普特公司 具有烟碱性胆碱能受体活性的氮杂螺烯和氮杂螺烷化合物
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
AU2007299920A1 (en) * 2006-09-19 2008-03-27 Braincells, Inc. PPAR Mediated Modulation of Neurogenesis
WO2008036846A2 (en) * 2006-09-22 2008-03-27 Braincells, Inc. Combination comprising an hmg-coa reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis
US20080108574A1 (en) * 2006-09-27 2008-05-08 Braincells, Inc. Melanocortin receptor mediated modulation of neurogenesis
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
EP2481408A3 (de) 2007-03-01 2013-01-09 Probiodrug AG Neue Verwendung von Inhibitoren der Glutaminyl Cyclase
EP2865670B1 (de) 2007-04-18 2017-01-11 Probiodrug AG Thioharnstoffderivative als Glutaminylcyclaseinhibitoren
TW200902007A (en) * 2007-05-25 2009-01-16 Astrazeneca Ab Spirocyclopropyl piperidine derivatives
US20100130477A1 (en) * 2008-11-25 2010-05-27 Astrazeneca Ab Spirocyclobutyl Piperidine Derivatives
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
WO2011100373A1 (en) 2010-02-09 2011-08-18 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
EP2545047B9 (de) 2010-03-10 2015-06-10 Probiodrug AG Heterocyclische hemmer der glutaminylcyclase (qc, ec 2.3.2.5)
EP2560953B1 (de) 2010-04-21 2016-01-06 Probiodrug AG Hemmer der glutaminylzyklase
WO2011143457A2 (en) 2010-05-12 2011-11-17 Northwestern University Compositions and methods for treating or preventing atrial fibrillation
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
EP3827820A1 (de) 2013-03-15 2021-06-02 The Johns Hopkins University Brivaracetam zur verbesserung der kognitiven funktion
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
EP3212637B1 (de) 2014-10-31 2021-06-02 Indivior UK Limited Dopamin d3 rezeptor antagonisten
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
WO2019126559A1 (en) * 2017-12-20 2019-06-27 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
TWI767148B (zh) * 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04225953A (ja) * 1990-05-07 1992-08-14 Shionogi & Co Ltd スピロ　ジベンゾスベラン誘導体
GB9309422D0 (en) * 1993-05-07 1993-06-23 Res Inst Medicine Chem Chemical compounds
WO1999032489A1 (en) * 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
US7164024B2 (en) * 2001-04-20 2007-01-16 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives

Also Published As

Publication number Publication date
JP2010059213A (ja) 2010-03-18
ES2315494T3 (es) 2009-04-01
AU2003228674A1 (en) 2003-11-10
JP2006507220A (ja) 2006-03-02
EP1499596B1 (de) 2008-11-05
CA2484217A1 (en) 2003-11-06
WO2003091220A1 (en) 2003-11-06
JP4527408B2 (ja) 2010-08-18
CN1649845A (zh) 2005-08-03
DE60324544D1 (de) 2008-12-18
ATE413388T1 (de) 2008-11-15
US20040067972A1 (en) 2004-04-08
MXPA04010552A (es) 2005-01-25
EP1499596A1 (de) 2005-01-26
US6890936B2 (en) 2005-05-10

Similar Documents

Publication Publication Date Title
HK1068136A1 (en) Muscarinic antagonists
CA2407100A1 (en) 1-aroyl-piperidinyl benzamidines
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
HK1155146A1 (zh) 作為藥物活性劑的茚衍生物
HK1048990A1 (en) Novel compounds.
PT1073470E (pt) Composicoes farmaceuticas contendo compostos com actividade capaz de melhorar a absorcao de ingredientes activos
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
IL129592A0 (en) 5-HT1f agonists
IL166271A0 (en) Pyrrolidinedione substituted piperidine phthalazone derivatives and pharmaceutical compositions containing the same
UA81624C2 (ru) Тризамещённые гетероарилы и способ их получения и применение
WO2002046170A8 (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
PL366198A1 (en) Novel compounds
BR0307833A (pt) Sìntese controlada de ziprasidona e suas composições
IL175409A0 (en) Oxazolidinone-quinolone hybrid derivatives and pharmaceutical compositions containing the same
ZA200203165B (en) 5-aryl-1H-1,2,4-triazole compounds as inhibitors of cyclo-oxygenase-2 and pharmaceutical compositions containing them.
SE0203070D0 (en) Novel compounds
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
BG105710A (en) 5ht1 antagonists for antidepressant therapy
BR0212899A (pt) Compostos orgânicos
PT1427417E (pt) Derivados de 6, 7-di-hidroxitetra-hidroisoquinolina substituída em 3 para utilização como agentes antibacterianos
MXPA03008801A (es) Aril oxima-piperazinas utiles como antagonistas de ccr5.
HK1077303A1 (en) Hexacyclic compounds
NO20002408D0 (no) 5-HT1F antagonister
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
GB0223223D0 (en) Organic compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130424